LinkedIn makes it clear that JeanMarie Guenot has over 20 years’ experience in the biotechnology and pharmaceutical industry. Her history has her working in public and private companies, in pharmaceutical R&D, she has a vast amount of experience in commercial development, project and alliance management, business development and venture capital.
She was a business advisor in Basel, Switzerland and Shanghai, China for Hoffmann-La Roche from 2008 to 2009, Before this she served as the Vice President of Corporate and Business Development for PDL’s BioPharma. In this position, she led mergers and acquisitions, licensing, and alliance management for PDL’s R&D and in commercial product portfolios.
Dr. Guenot negotiated an $800 million 50:50 co-development and commercialization collaboration that involved three 2 Phase autoimmune and cancer disease drug candidates. This transaction also included a $100 million equity investment in PDL. In 2005 she received the BioBusiness Network’s innovative Bio-Partnering Award, and in 2006 was awarded the Deal of Distinction from the Licensing Executives Society.
JeanMarie Guenot started her career managing venture capital investments at Atlas Venture. When she started her scientific career, it was as a principal scientist in preclinical R&D at Hoffman-La Roche where she developed drugs for metabolic diseases, autoimmune diseases, inflammation, and oncology. Her training is in physical and medicinal chemistry, focusing on quantum mechanical and methods for molecular dynamics, X-ray and NMR refinement and drug design.
Dr. Gueout graduated from the University of California, San Francisco where she received her Ph.D. and her MBA from the University of Pennsylvania, The Wharton School. All of which is covered on her website JeanmarieGuenot.com.
She is at present the President of Amphivena Therapeutics, where they are working to find treatment and therapies for hematological conditions and malignancies. Amphivena Therapeutics, Inc. is a developer of cancer immunotherapeutics. Under an agreement with Janssen Biotech they have selected a clinical candidate against a tumor antigen and will further development in hematologic malignancies.
JeanMarie Guenot’s experience has made her into a dynamic business woman who has a well-disciplined mind and can and does apply all that she has learned to help ease suffering and try to make the world a better place for everyone to live in. Jeanmarie has just negotiated a major partnership with Takeda, which you can read about on their website: https://www.takeda.com/news/2017/20170111_7659.html